Navigation Links
Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
Date:8/25/2009

SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that all patients enrolled in the Company's MATRIX clinical study have now completed their initial 12-week evaluation period and that it plans to provide detailed safety and efficacy data in late September 2009.

(Logo:http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

The Phase 2b MATRIX clinical trial is a prospective, randomized, double-blind, placebo-controlled study of Excellarate(TM) for the potential treatment of chronic diabetic foot ulcers. The clinical study is designed to evaluate safety and key efficacy measures including complete wound closure, time to complete wound closure, absolute and percent change in ulcer area, and wound healing trajectories at various time points, as well as a wide range of other safety and comparative healing metrics which will be used to develop a Phase 3 clinical study. In addition, following the initial 12-week efficacy evaluation period, patients whose wounds have successfully closed are now being followed for three months to further evaluate wound healing durability.

"With the data set now complete for the initial 12-week evaluation period, we look forward to completion of the formal statistical review and analysis and, as previously reported, we expect to announce safety and efficacy data around the end of September," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics. "During the course of this landmark gene therapy trial, we have observed some remarkable healing responses, based on a one or two physician-administered treatment proto
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Eisai Limited is pleased to ... the first-of-its-kind comic book available in Canada ... designed specifically to educate children and their parents about epilepsy, ... affecting more than 300,000 Canadians. Eisai is guided by ... , in which the patient is central – there was ...
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
(Date:8/21/2014)... , N.Y. and HAMBURG, Germany , ... announced it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ... Germany , to speed up management and storage ... Big Data and Analytics architecture based on IBM ... per second of data at peak performance and help ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... 15 Prometheus Laboratories Inc., a specialty pharmaceutical ... launch of three new cancer diagnostic products: ProOnc ... Dx. Each of these tests is based on ... has a long and successful history of providing ...
... Oct. 15 Aethlon Medical, Inc. (OTC Bulletin Board: ... treatment of Hepatitis-C (HCV) infected patients with the Aethlon ... & Scientific Exposition of the American Society of Nephrology ... studies and Director of Nephrology at the Fortis Hospital ...
Cached Medicine Technology:Prometheus Launches ProOnc Dx Cancer Diagnostics 2Prometheus Launches ProOnc Dx Cancer Diagnostics 3Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 2Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 3
(Date:8/22/2014)... UWDress.com, a leading online supplier of wedding dresses and women’s ... empire bridesmaid dresses to its product line. In addition ... these high quality items. All of them are now available ... , The company’s new items can definitely add beauty ... website. It is true that all its products are more ...
(Date:8/22/2014)... CA (PRWEB) August 22, 2014 Japantown ... offering a new teeth whitening technique. Air polishing is ... cleaning appointments. , Dark teeth can be caused by ... categories: external stains and internal stains. External stains include ... can be caused by certain medications, such as tetracycline, ...
(Date:8/22/2014)... Amy Norton HealthDay Reporter ... growing number of Americans on work disability chronically use ... Researchers found that between 2007 and 2011, about 44 ... were prescribed narcotic painkillers each year. And the percentage ... 2007 to 23 percent in 2011. Experts ...
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... that uses university-proven research to show people how they can ... lean muscle in only a matter of weeks has caught ... , “Ben Pakulski is one of the most well-known bodybuilders ... get the body he has today, that in itself is ...
Breaking Medicine News(10 mins):Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2Health News:Japantown Dental Introduces Air Polishing 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2
... to bring an end to the double–penalty system for health trusts ... a health trust falls into deficit, not only is it penalized ... money is cut off from its allocated funds from the ensuing ... health trusts find it virtually impossible to balance accounts and have ...
... Millions of Americans whose vision is slowly ebbing due to ... the lowly neural progenitor cell may be useful for restoring ... rats, neural progenitor cells derived from human fetal stem cells ... degenerative eye disease similar to the kinds of diseases that ...
... control high blood pressure and new drugs that target ... have designed two promising new cardiovascular treatment approaches, a ... to lower high blood pressure and a therapeutic hybrid ... ,In the process, they have overcome ...
... new study finds the popular anti-clotting drug clopidogrel (Plavix) when ... safe without any adverse bleeding event.// ,The ... 56th Annual Scientific Session on March 27 at 9 am ... aspirin, will not worsen bleeding after off-pump heart bypass surgery. ...
... multi-center study concludes that women with a recent diagnosis of ... opposite breast.// ,This study was conducted by ... ,The international research team found that MRI, or ... 30 of 969 women (3.1 percent) who had recently been ...
... considering vaccinating young girls against a virus that causes cervical ... Robert Koch-Institute in Germany has recommended the universal vaccination of ... ,The Italian Ministry of Health has announced that vaccination of ... as regional vaccination centers are prepared. ,Government ...
Cached Medicine News:Health News:Double-penalty System for Bankrupt Health Trusts Lifted 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 3Health News:Hormone-based Heart Pill to Control High Blood Pressure 2Health News:Hormone-based Heart Pill to Control High Blood Pressure 3Health News:Plavix Safe During and After Heart Bypass 2Health News:MRI Screening of Other Breast Crucial for Patients Diagnosed With Cancer in One Breast 2
... Thermo Scientific Finnpipette Dispenser cover all volumes ... very high consistency, precision and reproducibility, due ... The Finnpipette Dispenser range is the latest ... manual liquid handling products, offering users reliability ...
... compact, mobile femtosecond surgical laser, has been ... for a wide spectrum of applications in ... demand of refractive surgeons for an "all-Laser ... efficient LASIK work-flow. The solution by Ziemer ...
... EHEC is the first one-step 20 minutes rapid ... and 2 produced by Enterohemorrhagic Escherichia coli in ... overnight enrichment of fecal specimens and detects all ... The separate result for Toxin 1 and 2 ...
Inquire...
Medicine Products: